Sage Therapeutics Discontinues Dalzanemdor Development After Phase II Huntington's Disease Trial Failure
Key Insights
Sage Therapeutics halts development of dalzanemdor after disappointing Phase II results in Huntington's disease (search), marking the third failed indication for the NMDA modulator.
The trial failure leaves Sage with one commercial drug and three early-stage assets, significantly narrowing its pipeline prospects.
All four of Sage's planned clinical trial readouts for 2024 have been negative, impacting the company's R&D strategy.
Sage Therapeutics has announced the discontinuation of dalzanemdor development following its failure in a Phase II clinical trial for Huntington's disease (search). This setback marks the third unsuccessful indication for the NMDA modulator, significantly impacting Sage's pipeline prospects. The company now focuses on its one commercial drug and three early-stage assets.
The Phase II trial aimed to assess the efficacy and safety of dalzanemdor in patients with Huntington's disease (search). However, the drug did not meet its primary or secondary endpoints, leading to the decision to halt further development. This outcome follows other negative readouts from Sage's planned 2024 clinical trials.
The failure of dalzanemdor in Huntington's disease (search) represents a significant blow to Sage's R&D efforts, as it was a key asset in their mid-stage pipeline. The company will now need to reassess its strategy and prioritize its remaining assets.